Currie Graeme Martin 4/A
4/A · Pasithea Therapeutics Corp. · Filed Apr 5, 2024
Insider Transaction Report
Form 4/AAmended
Currie Graeme Martin
Chief Development Officer
Transactions
- Award
Stock Option (right to buy)
2024-03-01+5,938→ 5,938 totalExercise: $8.13Exp: 2034-02-28→ Common Stock (5,938 underlying)
Footnotes (2)
- [F1]The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share.
- [F2]The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The Option fully vested upon issuance and became exercisable on March 1, 2024.